Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. Journal Abstract

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study.

Publication Date: 2024 Sep

Full Text Sources

Authors

Madeleine J Karpinski; Johannes Hüsing; Kevin Claassen; Lennart Möller; Hiltraud Kajüter; Florian Oesterling; Viktor Grünwald; Lale Umutlu; Jens Kleesiek; Tugce Telli; Anja Merkel-Jens; Anika Hüsing; Claudia Kesch; Ken Herrmann; Matthias Eiber; Sebastian Hoberück; Philipp T Meyer; Felix Kind; Kambiz Rahbar; Michael Schäfers; Andreas Stang; Boris A Hadaschik; Wolfgang P Fendler

Abstract

OBJECTIVE

Prostate-specific membrane antigen (PSMA)-PET was introduced into clinical practice in 2012 and has since transformed the staging of prostate cancer. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria were proposed to standardise PSMA-PET reporting. We aimed to compare the prognostic value of PSMA-PET by PROMISE (PPP) stage with established clinical nomograms in a large prostate cancer dataset with follow-up data for overall survival.

Source

The Lancet. Oncology

Pub Types(s)

Journal Article

Language

English

PubMed ID

39089299